| scholarly article | Q13442814 |
| P2093 | author name string | K Yamada | |
| T Inoue | |||
| T Furukawa | |||
| M Domae | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 137-143 | |
| P577 | publication date | 1996-04-01 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland | |
| P478 | volume | 277 |
| Q34595128 | Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents |
| Q37696215 | Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study |
| Q44675329 | Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats |
| Q46446352 | Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors |
| Q58700667 | Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level |
| Q33841432 | Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans |
| Q35098039 | Aripiprazole maintenance increases smoked cocaine self-administration in humans |
| Q34375654 | Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. |
| Q34333899 | Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder |
| Q37322237 | Classifying antipsychotic agents : need for new terminology |
| Q34227284 | Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy |
| Q35688765 | Dopamine partial agonists: a new class of antipsychotic |
| Q48432762 | Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats. |
| Q34009852 | Effects of aripiprazole on subjective and physiological responses to alcohol |
| Q42661585 | Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole |
| Q84010902 | Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats |
| Q37299210 | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review |
| Q45916254 | Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. |
| Q46260468 | Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism |
| Q37400361 | Heart rate variability in depressed elderly |
| Q29616641 | How were new medicines discovered? |
| Q34605085 | Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies |
| Q37993473 | Is rational antipsychotic polytherapy feasible? A selective review |
| Q63951925 | Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization |
| Q47549788 | Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders |
| Q33186211 | Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study |
| Q26782978 | The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis |
| Q37316104 | Use of atypical antipsychotics for treatment-resistant major depressive disorder |
Search more.